Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

91.00 +2.32 (+2.62%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

73 74 Next >

Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move? ↗

April 23, 2025

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI.

Via Benzinga

Topics Artificial Intelligence

Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

April 22, 2025

Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.

Via MarketBeat

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ↗

April 21, 2025

AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results.

Via Benzinga

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

April 21, 2025

From AstraZeneca

Via Business Wire

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever ↗

April 17, 2025

Via The Motley Fool

Topics Government World Trade

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now ↗

April 14, 2025

A small amount of money can go a long way when it's invested in industry leaders with well-defined catalysts.

Via The Motley Fool

Topics Economy Government Stocks

Why the quality investor may take a look at ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN). ↗

April 12, 2025

A fundamental analysis of (NASDAQ:AZN): Why Quality Investors Should Delve into ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) for Investment Opportunities.

Via Chartmill

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗

April 10, 2025

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

Via Benzinga

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today ↗

April 09, 2025

Might the tariff risk for pharmaceutical stocks be less than you think?

Via The Motley Fool

Topics Government World Trade

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market ↗

April 09, 2025

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.

Via Benzinga

Topics Government World Trade

3 No-Brainer Growth Stocks to Buy for Less Than $100 ↗

April 09, 2025

Via The Motley Fool

European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings ↗

April 04, 2025

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing significant survival benefits.

Via Benzinga

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday ↗

April 03, 2025

Via The Motley Fool

Topics Economy Government World Trade

Peering Into AstraZeneca's Recent Short Interest ↗

April 01, 2025

Via Benzinga

FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients ↗

March 31, 2025

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

Via Benzinga

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗

March 31, 2025

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Via Investor's Business Daily

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

March 31, 2025

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

March 31, 2025

From AstraZeneca

Via Business Wire

Competitive Analysis In The ATTR-CM Field ↗

March 30, 2025

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...

Via Talk Markets

Topics Stocks / Equities

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug ↗

March 27, 2025

BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it.

Via Benzinga

J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study ↗

March 26, 2025

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib.

Via Benzinga

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

March 27, 2025

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

March 25, 2025

From AstraZeneca

Via Business Wire

Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead ↗

March 23, 2025

Via The Motley Fool

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Two Sectors Just Tried And Failed - And That’s Great For Us ↗

March 20, 2025

Technology and healthcare have both tried for a breakout and failed, courtesy of massive economic forces rocking the boat.

Via Talk Markets

Topics Stocks / Equities

A Potential Challenger For AstraZeneca's Blockbuster Lung Cancer Drug? ↗

March 20, 2025

AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions